TAKE enterprise value

·Pharma & HealthChart ›
MultiplesEnterprise valuePer share
Share price at each year-end
Tap a line for its trendCurrentlast 12MFY26Mar 2026FY25Mar 2025FY24Mar 2024FY23Mar 2023FY22 and earlierAlpha Plus
164————
FY22 and earlierEvery year the company has filed comes with Alpha Plus.
0.30.33.40.810.7
0.00.00.00.0—
0.00.00.028.033.3
163————
−0.3−0.3−3.427.122.5
₹11.04————
31.031.020.519.1142
0.0%0.0%0.0%146.5%23.4%
1.93×————
−94.44×————
−94.10×————
Reference items — trailing FY values
84.654.20.065.6189
−1.7−1.9−7.5−13.5−19.0
−1.7−1.9−7.5−21.3−35.9
—−4.1−16.49.320.0
−4.1−4.1−16.41.412.2
—−4.1−16.41.412.2
—0.00.07.97.8
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

TAKE₹11.06

TAKE Limited

· Pharma & Health
₹ CrorePeersVIMTALABSSUVENMcap ₹164 Cr
HighlightsEnterprise ValueMultiplesPer ShareAnnuals · FY-end closes
In ₹ Crore except Per Share
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Current/LTM
TTM · last close
Market Capitalization————163.6
- Cash, Equiv & ST Investments10.70.83.40.30.3
+ Minority Interest—0.00.00.00.0
+ Total Debt33.328.00.00.00.0
Enterprise Value————163.4
Net Debt (memo)22.527.1-3.4-0.3-0.3
EV per Share————11.04
Total Capital141.919.120.531.031.0
Total Debt/Total Capital23.44146.490.000.000.00
EV/Sales————1.93
EV/EBITDA————-94.44
EV/EBIT————-94.10
Reference Items — Trailing FY Values
Sales189.165.60.054.284.6
EBITDA-19.0-13.5-7.5-1.9-1.7
EBIT-35.9-21.3-7.5-1.9-1.7
Operating Cash Flow20.09.3-16.4-4.1—
Free Cash Flow12.21.4-16.4-4.1-4.1
FCFF (free cash flow to the firm)12.21.4-16.4-4.1—
Capital Expenditure7.87.90.00.0—
Market Cap/EV/multiples pair each (split/bonus-adjusted) FY-end close with the latest filed share count; Current column uses the last close. Market Capitalization is a market-level figure — identical across Consolidated/Standalone (the accounting rows below differ). No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.